Methods for the treatment of childhood-onset fluency disorder
AssigneeNoema Pharma AG
InventorGeorge Garibaldi
Life of this patent
Estimating the term…
Abstract
Provided herein are methods of treating Childhood-Onset Fluency Disorder (COFD) in a subject in need thereof by administering to the subject compositions comprising a PDE10A inhibitor. Also disclosed are methods of treating COFD in a subject in need thereof by administering to the subject compositions comprising the compound of Formula I below:
Claims72
A method of treating Childhood-Onset Fluency Disorder (COFD), comprising administering to a subject in need thereof a composition containing a therapeutically effective amount of a phosphodiesterase 10A (PDE10A) inhibitor or a pharmaceutically acceptable salt thereof.
A method of treating Childhood-Onset Fluency Disorder (COFD), comprising administering to a subject in need thereof a composition containing a therapeutically effective amount of a therapeutic agent or a pharmaceutically acceptable salt thereof, wherein the therapeutic agent is a compound of Formula I:
A method of treating COFD, comprising administering to a subject in need thereof a composition containing a therapeutically effective amount of a therapeutic agent or a pharmaceutically acceptable salt thereof, wherein the therapeutic agent is a compound of Formula I:
- wherein administering comprises administering the compound of Formula I, or a pharmaceutically acceptable salt thereof, in an amount of about 5 mg to about 15 mg once daily.
A method of treating COFD, comprising administering to a subject in need thereof a composition containing a therapeutically effective amount of a therapeutic agent or a pharmaceutically acceptable salt thereof, wherein the therapeutic agent is a compound of Formula I:
- wherein administering comprises administering the compound of Formula I, or a pharmaceutically acceptable salt thereof, in an amount of about 2.5 mg to about 15 mg once daily.
A method of treating COFD, comprising administering to a subject in need thereof a composition containing a therapeutically effective amount of a crystalline solid of the compound of Formula I:
- wherein said crystalline solid has a melting point onset as determined by DSC of about 210° C. to about 214° C., and said administering comprises administering the crystalline solid in an amount of about 2.5 mg to about 15 mg once daily.
A method of treating Childhood-Onset Fluency Disorder (COFD) in a subject in need thereof, comprising administering to a subject in need thereof a therapeutically effective amount of:
- a compound of Formula III:
- and
- a compound of Formula I:
- or a pharmaceutically acceptable salt thereof.
A method of treating Childhood-Onset Fluency Disorder (COFD) in a subject in need thereof, comprising administering to a subject in need thereof a therapeutically effective amount of:
- a compound of the compound of Formula III:
- and
- a crystalline solid of Formula I:
- wherein said crystalline solid has a melting point onset as determined by DSC of about 210° C. to about 214° C.;
- or a pharmaceutically acceptable salt thereof.
A method of treating Childhood-Onset Fluency Disorder (COFD) in a subject in need thereof, comprising administering to a subject in need thereof a therapeutically effective amount of:
- a compound of Formula III:
- and
- a compound of Formula I:
- or a pharmaceutically acceptable salt thereof, wherein the compound of Formula III, or a pharmaceutically acceptable salt thereof, is administered at about 2.5 mg to about 5.0 mg once daily;
- and the compound of Formula I, or a pharmaceutically acceptable salt thereof, is administered at about 5.0 mg to about 15 mg once daily.
A method of treating Childhood-Onset Fluency Disorder (COFD) in a subject in need thereof, comprising administering to a subject in need thereof a therapeutically effective amount of:
- a compound of Formula III:
- and
- a crystalline solid of Formula I:
- or a pharmaceutically acceptable salt thereof, wherein the compound of Formula III, or a pharmaceutically acceptable salt thereof, is administered at about 2.5 mg to about 5.0 mg once daily;
- and the compound of Formula I, or a pharmaceutically acceptable salt thereof, is administered at about 5.0 mg to about 15 mg once daily.
Dependencies are inferred from the claim text.